Anti-angiogenic compounds based on modulation of VEGF splicing
Lead Research Organisation:
University of Bristol
Department Name: Physiology and Pharmacology
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
Publications
Barratt S
(2017)
Differential Expression of VEGF-A xxx Isoforms Is Critical for Development of Pulmonary Fibrosis
in American Journal of Respiratory and Critical Care Medicine
Bates DO
(2018)
Physiological Role of Vascular Endothelial Growth Factors as Homeostatic Regulators.
in Comprehensive Physiology
Bates DO
(2017)
Pharmacology of Modulators of Alternative Splicing.
in Pharmacological reviews
Bowler E
(2019)
Alternative Splicing in Angiogenesis.
in International journal of molecular sciences
Bullock N
(2017)
The many faces of SRPK1.
in The Journal of pathology
Bullock N
(2016)
Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion.
in Journal of clinical pathology
Kikuchi R
(2019)
Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease.
in Advances in clinical chemistry
Legge D
(2022)
The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor.
in Molecular oncology
Li L
(2022)
A repositioning screen using an FGFR2 splicing reporter reveals compounds that regulate epithelial-mesenchymal transitions and inhibit growth of prostate cancer xenografts.
in Molecular therapy. Methods & clinical development
| Description | This award was used to explore whether a certain technology developed in my lab may be further developed and used for drug development, especially referring todrugs that affect growth of vessels.the market research done has given us clear durections on how to proceed. |
| Exploitation Route | This project relates to drug development in the area of blood vessel growth. The findings may be used in the future to develop new drugs for diabetes, cancer or certain eye diseases. |
| Sectors | Pharmaceuticals and Medical Biotechnology |
| Description | Determining tissue uptake and retention of lead compounds identified for improving organ / tissue preservation and transplantation |
| Amount | £44,952 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2019 |
| End | 05/2020 |
| Description | Project grant |
| Amount | £163,071 (GBP) |
| Funding ID | 17/0005668 |
| Organisation | Diabetes UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 06/2020 |